Cantor Fitzgerald Comments on Allakos Inc.’s Fiscal Year 2022 Results (NASDAQ:ALLK)
Allakos Inc. (NASDAQ:ALLK – Get Rating) – Stock analysts Cantor Fitzgerald cut their fiscal 2022 EPS estimates for Allakos shares in a research report released Thursday, May 19. Cantor Fitzgerald analyst J. Kim now expects the company to post earnings per share of ($5.83) for the year, down from its previous estimate of ($5.29). $). Cantor Fitzgerald has an “overweight” rating on the stock.
Several other stock analysts have also recently weighed in on ALLK. Zacks Investment Research downgraded Allakos shares from a “held” rating to a “strong sell” rating in a Tuesday, May 10 research note. SVB Leerink reduced its price target on Allakos shares from $17.00 to $13.00 and set a “market performance” rating on the stock in a Wednesday, February 16 research note. Two analysts rated the stock with a sell rating, seven gave the company a hold rating and two assigned a buy rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $60.22.
NASDAQ: ALLK opened at $3.00 on Monday. The company’s 50-day moving average price is $4.74 and its 200-day moving average price is $23.40. The company has a market capitalization of $164.33 million, a P/E ratio of -0.40 and a beta of 0.96. Allakos has a 12-month low of $2.77 and a 12-month high of $11.73.
Allakos (NASDAQ:ALLK – Get Rating) last released quarterly earnings data on Friday, May 6. The company reported ($3.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by ($1.65).
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Credit Suisse AG increased its holdings of Allakos shares by 0.7% in the third quarter. Credit Suisse AG now owns 27,019 shares in the company valued at $2,860,000 after buying 188 more shares last quarter. Arizona State Retirement System increased its position in Allakos by 2.2% during the third quarter. Arizona State Retirement System now owns 8,755 shares of the company worth $927,000 after buying 192 additional shares in the last quarter. UBS Asset Management Americas Inc. increased its position in Allakos by 2.2% during the third quarter. UBS Asset Management Americas Inc. now owns 35,031 shares of the company worth $3,709,000 after purchasing an additional 765 shares in the last quarter. CNA Financial Corp increased its stake in Allakos shares by 16.4% during the third quarter. CNA Financial Corp now owns 6,330 shares of the company worth $670,000 after purchasing an additional 890 shares during the period. Finally, Teacher Retirement System of Texas increased its stake in Allakos shares by 23.4% during the 3rd quarter. Teacher Retirement System of Texas now owns 5,075 shares of the company worth $537,000 after purchasing an additional 961 shares during the period. Institutional investors hold 61.07% of the company’s shares.
Allakos Company Profile (Get an assessment)
Allakos Inc, a clinical-stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergic, inflammatory and proliferative diseases. The company’s lead monoclonal antibody is lirentelimab (AK002), which is in a phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a phase II/III study for eosinophilic esophagitis; and a phase II clinical study in atopic dermatitis and chronic spontaneous urticaria.
Get news and reviews for Allakos Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Allakos and related companies with MarketBeat.com’s free daily email newsletter.